You are viewing: Rest Of GCC Countries Plasma Fractionation Market analysis
Part of: Plasma Fractionation Market (Global)

The Rest Of GCC Countries Plasma Fractionation Market was valued at $85.1 Million in 2026 and projected to reach to $105.6 Million by 2031, representing a compound annual growth rate of CAGR 4.4%. Rest Of GCC Countries plasma fractionation market is positioned for steady growth through 2031, supported by expanding healthcare budgets and increasing prevalence of immunodeficiency disorders, hemophilia, and bleeding disorders.

Rest Of GCC Countries Plasma Fractionation Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Rest Of GCC Countries Plasma Fractionation Market Trends and Insights

  • Rest Of GCC Countries is experiencing steady expansion driven by increasing demand for immunoglobulin therapies, clotting factor concentrates, and albumin products.
  • The region's healthcare infrastructure improvements and rising prevalence of bleeding disorders and immunodeficiency conditions are supporting market growth throughout the forecast period. Rest Of GCC Countries benefits from growing healthcare expenditure and enhanced access to plasma-derived therapies across the region.
  • The market in Rest Of GCC Countries is characterized by a mix of imported products and emerging local manufacturing capabilities.
  • Between 2026 and 2031, Rest Of GCC Countries is expected to see increased adoption of advanced fractionation technologies and expanded distribution networks, positioning the region as a growing hub for plasma therapeutics in the Middle East..

Key Market Statistics

  • CAGR (2026-2031) CAGR 4.4%
  • Market Size, 2026 ~USD 85.1 Million
  • Forecast, 2031 ~USD 105.6 Million
  • Country Rest Of GCC Countries

Rest Of GCC Countries Plasma Fractionation Market Overview

Market Size & Growth :

Rest Of GCC Countries plasma fractionation market valued at USD 85.1 million in 2026, expanding to USD 105.6 million by 2031 with a steady 4.4% CAGR, outpacing some regional peers.

Product Demand Drivers :

Increasing adoption of immunoglobulin therapies, clotting factor concentrates, and albumin products across Rest Of GCC Countries healthcare facilities, driven by rising patient populations and chronic disease prevalence.

Healthcare Infrastructure Growth :

Rest Of GCC Countries investing in modern healthcare infrastructure and plasma collection centers, supporting local fractionation capacity and reducing import dependency for critical blood products.

Regional Market Dynamics :

Rest Of GCC Countries benefits from GCC healthcare standardization initiatives and cross-border medical cooperation, creating opportunities for plasma fractionation product distribution and partnerships.

Rest Of GCC Countries Plasma Fractionation Market Dynamics

  • The region's focus on self-sufficiency in blood product manufacturing and regulatory harmonization with neighboring GCC nations will drive market expansion.
  • Healthcare providers in Rest Of GCC Countries are increasingly prioritizing plasma-derived therapies as essential components of modern treatment protocols, particularly for rare diseases and critical care applications.
  • Investment in plasma collection infrastructure and fractionation facilities will enhance market accessibility and reduce treatment costs for local populations..

Market Ecosystem

logo-mobile

PLASMA FRACTIONATION MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Implemented the Horizon 2 plasma fractionation process at its Kankakee facility to improve immunoglobulin recovery from donated plasma Higher immunoglobulin yield | Improved plasma utilization | Greater production efficiency | Increased supply capacity
company logo
Implemented process improvements through its One Day Batch Release program at plasma-derived therapy manufacturing sites to accelerate batch release Faster batch release | Improved manufacturing efficiency | Shorter lead times | Faster product availability

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Pharmaceuticals

    Top Technologies
    • Bioreactors
    • Analytical Testing
    • Bioanalytical Testing Services
    • Cell Counters
    • Data Management Services
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • SANOFI
    • Pfizer Inc.
    • NOVARTIS

      Key Takeaways

      • Rest Of GCC Countries plasma fractionation market valued at USD 85.1 million in 2026, expanding to USD 105.6 million by 2031
      • Rest Of GCC Countries demonstrates a 4.4% CAGR, reflecting moderate but consistent market growth over the forecast period
      • Rest Of GCC Countries is driven by rising immunoglobulin demand, improved healthcare infrastructure, and increased bleeding disorder prevalence
      • Rest Of GCC Countries market is transitioning toward local manufacturing and advanced fractionation technologies by 2031

      Plasma Fractionation Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment SCIG (Type)
      Forecast Period 2026-2030
      Growth Rate CAGR of 7.6% from 2026 to 2030
      Largest Segment THERAPEUTICS (Application)
      Market Size Base Year (Billions) ~USD 36.46 (2026)
      Revenue Forecast (Billions) ~USD 48.87 (2030)
      Segments Covered Product, Type, Application, Therapeutic Area, End User

      Rest Of GCC Countries Plasma Fractionation Market Report Segmentation

      5 segment dimensions are covered across the global market.

      By Product

      • Albumin
      • Coagulation Factor Concentrates
      • Immunoglobulins
      • Other Plasma Products
      • Protease Inhibitors

      By Type

      • Factor Ix
      • Factor Viii
      • Factor Xiii
      • Fibrinogen Concentrates
      • Ivig
      • Other Coagulation
      • Other Coagulation Factor Concentrates
      • Other Immunoglobulins
      • Prothrombin Complex Concentrates
      • Prothrombin Factor Concentrates
      • Scig
      • Von Willebrand Factor

      By Application

      • Academics & Preclinical Research
      • Therapeutics

      By Therapeutic Area

      • Critical Care
      • Hemato-Oncology
      • Hematology
      • Immunology
      • Neurology
      • Other Therapeutic Areas
      • Pulmonology
      • Rheumatology

      By End User

      • Home Care Settings & Infusion Centers
      • Hospitals & Specialty Clinics
      • Other End Users

      Target Audience

      • Plasma Fractionation Manufacturers : Manufacturers need Rest Of GCC Countries market data to assess market entry feasibility, competitive landscape, and growth potential for plasma-derived products in this steady-growth regional market.
      • Healthcare Providers & Hospital Networks : Hospital administrators and procurement teams require market insights to forecast plasma product demand, budget allocation, and supply chain planning for Rest Of GCC Countries patient populations.
      • Pharmaceutical Distributors & Wholesalers : Distribution partners need Rest Of GCC Countries-specific market data to optimize inventory management, identify growth segments, and develop targeted sales strategies for plasma fractionation products.
      • Investment & Private Equity Firms : Investors evaluating healthcare opportunities in Rest Of GCC Countries require validated market sizing and growth forecasts to assess investment returns and portfolio diversification in plasma fractionation.
      • Government & Healthcare Policy Makers : Regulatory bodies and health ministries in Rest Of GCC Countries need market intelligence to inform healthcare policy, plasma collection initiatives, and self-sufficiency strategies for blood products.

      Reasons to Buy this Report

      • Precise Market Sizing : Access validated market size data specific to Rest Of GCC Countries with accurate 2026 baseline (USD 85.1M) and 2031 forecast (USD 105.6M), enabling confident investment and expansion planning.
      • Regional Growth Insights : Understand the 4.4% CAGR trajectory unique to Rest Of GCC Countries, identifying growth opportunities distinct from global 7.6% CAGR and tailoring market entry strategies accordingly.
      • Product-Specific Demand Analysis : Gain detailed intelligence on immunoglobulin therapies, clotting factor concentrates, and albumin product demand patterns specific to Rest Of GCC Countries healthcare systems and patient populations.
      • Competitive Positioning : Benchmark your organization against Rest Of GCC Countries market dynamics, healthcare infrastructure investments, and regulatory environment to identify competitive advantages and partnership opportunities.
      • Strategic Decision Support : Leverage Rest Of GCC Countries-specific market intelligence for portfolio development, pricing strategy, distribution channel selection, and resource allocation decisions in this emerging regional market.

      Frequently asked questions

      What is the market size of plasma fractionation in Rest Of GCC Countries?

      Rest Of GCC Countries plasma fractionation market is valued at USD 85.1 million in 2026 and is forecast to reach USD 105.6 million by 2031.

      What is the expected growth rate for Rest Of GCC Countries plasma fractionation market?

      Rest Of GCC Countries plasma fractionation market is expected to grow at a CAGR of 4.4% from 2026 to 2031.

      What are the primary drivers of growth in Rest Of GCC Countries?

      Rest Of GCC Countries market growth is driven by increasing demand for immunoglobulin therapies, rising prevalence of bleeding disorders, improved healthcare infrastructure, and enhanced access to plasma-derived therapeutics.

      Which plasma products are most in demand in Rest Of GCC Countries?

      Rest Of GCC Countries shows strong demand for immunoglobulin therapies, clotting factor concentrates, and albumin products, reflecting the region's clinical needs and patient demographics.

      Is Rest Of GCC Countries developing local plasma fractionation manufacturing?

      Rest Of GCC Countries market is characterized by a mix of imported products and emerging local manufacturing capabilities, with expectations for increased local production by 2031.

      RESEARCH METHODOLOGY

      This research study extensively used secondary sources, directories, and databases to identify and collect valuable information for analyzing the global plasma fractionation market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size..

      Secondary Research

      The secondary sources for this research study include publications from government sources, such as FDA/CBER, EMA, WHO, and national health and regulatory authorities; industry associations, such as the Plasma Protein Therapeutics Association (PPTA), the International Plasma and Fractionation Association (IPFA), and AABB; and commercial databases, such as Bloomberg Business, D&B, Factiva, and relevant trade databases. Additional sources include white papers, annual reports, company house documents, investor presentations, scientific and clinical publications, regulatory filings, patent databases, and product and clinical trial databases. Secondary research was used to identify and collect information for the extensive, technical, market-oriented, and commercial study of the plasma fractionation market. It was also used to obtain important information about key players, market classification, segmentation according to industry trends, the bottom-up approach, and key developments from market and technology perspectives. Secondary data was also used to assess plasma collection capacity, fractionation and manufacturing infrastructure, product portfolios, regulatory frameworks, trade patterns, clinical applications, and regional market trends. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market’s prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative information.

      Plasma Fractionation Market
 Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the plasma fractionation market. These methods were also used extensively to estimate the size of various market segments.

      Plasma Fractionation Market : Top-Down and Bottom-Up Approach

      Plasma Fractionation Market Top Down and Bottom Up Approach

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.

      Market Definition

      Plasma-derived therapies are medical treatments based on human plasma. Plasma is the largest component of human blood and contains water, salts, enzymes, antibodies, and other proteins. Before it can be used in medical therapies, it undergoes a fractionation process in which the relevant proteins are separated. Plasma-derived therapies are used to treat a wide range of (rare) diseases, from bleeding disorders and inhibitor deficiencies to primary and secondary immunodeficiencies.

      Key Stakeholders

      • Plasma Fractionation Product Manufacturers and Distributors
      • Pharmaceutical and Biotechnology Companies
      • Healthcare Service Providers (including Hospitals and Clinics)
      • Research and Development (R&D) companies
      • Academic Institutes
      • Government Associations
      • Market Research and Consulting Firms
      • Venture Capitalists and Investors

      Report Objectives

      • To define, describe, and forecast the plasma fractionation market based on product, application, therapeutic area, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall plasma fractionation market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the plasma fractionation market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the plasma fractionation market
      • To benchmark players within the plasma fractionation market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product/service strategy

      Available customizations:

      With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

      Product Analysis

      • Further breakdown of the Rest of Europe Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Asia Pacific Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Latin America Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Middle East Plasma Fractionation Market, by country

      Company Information

      • Detailed analysis and profiling of additional market players (up to five)

      Get the Full Plasma Fractionation Market Report

      Full forecast, segment splits, and company analysis for all Plasma Fractionation Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status